1. Acquas E, Carboni E, De Ree RH, Da Prada M, Di Chlara G (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J Neurochem 59: 326–330
2. Ahtila S, Kaakkola S, Gordin A, Korpela K, Hein-Avaara S, Karlsson M, Wikberg T, Tuomainen P, Männistö PT (1995) Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 18: 46–57
3. Backstrom R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Linden IB, Männistö PT, Kaakkola S, et al. (1989) Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J Med Chem 32: 841–846
4. Bieck PR, Nilsson E, Antonin KH (1990) Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (30MD) in plasma of healthy subjects. J Neural Transm [Suppl] 32: 387–391
5. Bieck PR, Antonin KH, Farger G, Nilsson EB, Schmidt EK, Dostert P, Strolin Benedetti M, Waldmeier PC (1993) Clinical pharmacology of the new COMT inhibitor CGP 28,014. Neurochem Res 18: 1163–1167